Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

Healthcare Drug Manufacturers - Specialty & Generic
VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

VIVO Cannabis Inc.
Bullboard Posts
User Avatar Image
(16)
•••
Comment by Goalkeeper1on Oct 05, 2018 3:19pm
114 Views
Post# 28754472

RE:disgusted with myself for holding

RE:disgusted with myself for holding
Sig's,maybe this is where you saw the word vivo.


Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative delivery platform, DehydraTECH™, has demonstrated excellent results in delivery of nicotine to the brain in a recent lab study. An article discussing this reads, “The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (https://nnw.fm/oN1Xp). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s, schizophrenia and depression, it is now theorized that DehydraTECH could offer similar delivery advantages.
Cheer
Gk1

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities